The Lancet

The study, the second major clinical validation of the test, was published in the same week that Cepheid reported strong first-quarter results and several financial analysts raised their earnings estimates for the company.

Findings in a NEJM study this week challenged previously reported data that alleles in the CYP2C19 gene can limit how certain carriers of the polymorphisms respond to Plavix.